Thailand's Cost Control Measures And What They Mean For Pharma - IMS Analysis
This article was originally published in PharmAsia News
Executive SummarySHANGHAI - Thailand's recent clampdown on public healthcare spending means multinational drug makers will have to look for news ways to tap the country's drug market, according to IMS Health
You may also be interested in...
South Korea repeatedly faced drug supply disruptions when dealing with the outbreak of bird flu and new influenza, and when pharma firms refused to produce inexpensive but essential medicines, or drugs for rare diseases, due to low profitability. A local research paper now says the country may need a state-run pharma to ensure stable future supplies of essential medicines.
Thailand’s efforts to harmonize its health schemes has made progress on administration for claims and purchasing, but merging benefits into a common offering is a work in progress.
The president of the National Health Insurance Service told lawmakers his agency is assessing the feasibility of a state-owned pharma, which the domestic industry group said could put a pinch on reimbursement negotiations.